Skip to main content

Animations

MJFF Publications

1881 - 1890 of 6466 Results
Title
Year
  • Year
  • 2020
  • 2014
  • 2026
  • 2022
  • 2018
  • 2021
  • 2025
  • 2018
  • 2017
  • 2026
  • Summary Details
    OPEN
    Title: Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues
    Journal Name: Cells
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/cells9112344
    Citation Count: 60
  • Summary Details
    OPEN
    Title: Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer’s disease brains and human microglia
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2014.09.052
    Citation Count: 55
  • Summary Details
    OPEN
    Title: Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(26)00029-3
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype
    Journal Name: Molecular Therapy
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.ymthe.2022.01.021
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)
    Journal Name: Journal of Neuropathology & Experimental Neurology
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/jnen/nly056
    Citation Count: 37
  • Summary Details
    OPEN
    Title: Small Molecule Improvement of Trafficking Defects in Models of Neurodegeneration
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acschemneuro.1c00524
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Allogeneic Bone Marrow‐Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.70028
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Validation of a performance‐based assessment of cognitive functional ability in Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27487
    Citation Count: 21
  • Summary Details
    OPEN
    Title: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease
    Journal Name: Acta Neuropathologica Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40478-017-0456-2
    Citation Count: 100
  • Summary Details
    OPEN
    Title: Accelerating Medicines Partnership® Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.70183
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.